Cytokine storm syndrome in severe COVID-19.
作者信息
Ruscitti Piero, Berardicurti Onorina, Iagnocco Annamaria, Giacomelli Roberto
机构信息
Division of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Division of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
出版信息
Autoimmun Rev. 2020 Jul;19(7):102562. doi: 10.1016/j.autrev.2020.102562. Epub 2020 May 3.
Abstract
摘要
相似文献
1
Cytokine storm syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子风暴综合征
Autoimmun Rev. 2020 Jul;19(7):102562. doi: 10.1016/j.autrev.2020.102562. Epub 2020 May 3.
2
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?托珠单抗治疗新型冠状病毒肺炎细胞因子风暴综合征：念珠菌血症风险增加？
Autoimmun Rev. 2020 Jul;19(7):102564. doi: 10.1016/j.autrev.2020.102564. Epub 2020 May 5.
3
Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.为何适时进行的抗白细胞介素6治疗可能对重症COVID-19感染有益。
Autoimmun Rev. 2020 Jul;19(7):102563. doi: 10.1016/j.autrev.2020.102563. Epub 2020 May 5.
4
To immunosuppress: whom, when and how? That is the question with COVID-19.进行免疫抑制：对象是谁、何时进行以及如何进行？这就是新冠病毒病面临的问题。
Ann Rheum Dis. 2020 Sep;79(9):1129-1131. doi: 10.1136/annrheumdis-2020-218694. Epub 2020 Aug 4.
5
Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.英夫利昔单抗可将新冠肺炎危重症患者的死亡率从35%降至14%：或许有一些潜在混杂因素需要考虑。
Crit Care. 2020 Oct 9;24(1):603. doi: 10.1186/s13054-020-03294-7.
6
Imatinib might constitute a treatment option for lung involvement in COVID-19.伊马替尼可能构成COVID-19肺部受累的一种治疗选择。
Autoimmun Rev. 2020 Jul;19(7):102565. doi: 10.1016/j.autrev.2020.102565. Epub 2020 May 3.
7
Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?COVID-19 与抗 MDA5 综合征的相似之处：我们能从中吸取哪些经验以改善治疗？
Eur Respir J. 2020 Sep 24;56(3). doi: 10.1183/13993003.01618-2020. Print 2020 Sep.
8
Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?针对危重症 COVID-19 患者的细胞因子风暴综合征，血液净化疗法是否有作用？
Ren Fail. 2020 Nov;42(1):483-488. doi: 10.1080/0886022X.2020.1764369.
9
Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.COVID-19 患者中的风暴、台风、旋风或飓风？当心来自不同起源的相同风暴。
RMD Open. 2020 May;6(1). doi: 10.1136/rmdopen-2020-001295.
10
COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.COVID-19、肥大细胞、细胞因子风暴、心理压力和神经炎症。
Neuroscientist. 2020 Oct-Dec;26(5-6):402-414. doi: 10.1177/1073858420941476. Epub 2020 Jul 18.
引用本文的文献
1
Terpenes and cannabidiol against human corona and influenza viruses-Anti-inflammatory and antiviral in vitro evaluation.萜类化合物和大麻二酚对人类冠状病毒和流感病毒的作用——体外抗炎和抗病毒评估
Biotechnol Rep (Amst). 2024 Jan 17;41:e00829. doi: 10.1016/j.btre.2024.e00829. eCollection 2024 Mar.
2
Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection.血浆血管性血友病因子和含血小板解聚蛋白及金属蛋白酶13的动态评估可预测新型冠状病毒肺炎住院患者的死亡率
J Clin Med. 2023 Nov 19;12(22):7174. doi: 10.3390/jcm12227174.
3
The prevalence and contributing risk factors of coronavirus disease 2019 infection in patients with metabolic syndrome.代谢综合征患者中 2019 年冠状病毒病感染的流行情况和促成危险因素。
BMC Endocr Disord. 2023 May 4;23(1):100. doi: 10.1186/s12902-023-01351-0.
4
Increased Incidence of Pancreatic Steatosis Detected Using Computed Tomography at Initial Diagnosis of Coronavirus Disease 2019.在新冠肺炎初始诊断时，使用计算机断层扫描检测到胰腺脂肪变性的发病率增加。
Turk J Gastroenterol. 2023 Mar;34(3):270-277. doi: 10.5152/tjg.2023.22471.
5
Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models.植物大麻素与非甾体抗炎药协同作用，在二维和三维体外模型中减轻炎症。
Pharmaceuticals (Basel). 2022 Dec 14;15(12):1559. doi: 10.3390/ph15121559.
6
Endoplasmic reticulum secretory pathway: Potential target against SARS-CoV-2.内质网分泌途径：抗 SARS-CoV-2 的潜在靶点。
Virus Res. 2022 Oct 15;320:198897. doi: 10.1016/j.virusres.2022.198897. Epub 2022 Aug 18.
7
as Add-On Therapy for COPD Patients: A Randomized, Placebo-Controlled, Double-Blind Study.作为慢性阻塞性肺疾病患者的附加治疗：一项随机、安慰剂对照、双盲研究。
Front Pharmacol. 2022 Jun 16;13:901710. doi: 10.3389/fphar.2022.901710. eCollection 2022.
8
Associations and Disease-Disease Interactions of COVID-19 with Congenital and Genetic Disorders: A Comprehensive Review.COVID-19 与先天性和遗传疾病的关联及疾病间相互作用：全面综述。
Viruses. 2022 Apr 27;14(5):910. doi: 10.3390/v14050910.
9
Levosimendan Ameliorates Cardiopulmonary Function but Not Inflammatory Response in a Dual Model of Experimental ARDS.左西孟旦改善实验性急性呼吸窘迫综合征双模型中的心肺功能，但不改善炎症反应。
Biomedicines. 2022 Apr 29;10(5):1031. doi: 10.3390/biomedicines10051031.
10
Peptide-Based Vaccines and Therapeutics for COVID-19.用于治疗新冠肺炎的基于肽的疫苗和疗法
Int J Pept Res Ther. 2022;28(3):94. doi: 10.1007/s10989-022-10397-y. Epub 2022 Apr 19.
本文引用的文献
1
Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.新冠（COVID-19）时期的思考：我们在新冠病毒致病机制、诊断、治疗及疫苗研发计划中的参与情况
Autoimmun Rev. 2020 Jun;19(6):102538. doi: 10.1016/j.autrev.2020.102538. Epub 2020 Apr 5.
2
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.细胞因子（包括白细胞介素 6）在 COVID-19 诱导性肺炎和巨噬细胞活化综合征样疾病中的作用。
Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.
3
Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia.新型冠状病毒肺炎外周血淋巴细胞亚群特征变化。
J Infect Dis. 2020 May 11;221(11):1762-1769. doi: 10.1093/infdis/jiaa150.
4
Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?严重急性呼吸综合征冠状病毒2能否在遗传易感人群中引发自身免疫和/或自身炎症机制？
Autoimmun Rev. 2020 May;19(5):102524. doi: 10.1016/j.autrev.2020.102524. Epub 2020 Mar 24.
5
SARS-CoV-2: a storm is raging.新型冠状病毒：风暴正在肆虐。
J Clin Invest. 2020 May 1;130(5):2202-2205. doi: 10.1172/JCI137647.
6
Functional exhaustion of antiviral lymphocytes in COVID-19 patients.新冠病毒肺炎患者抗病毒淋巴细胞的功能耗竭
Cell Mol Immunol. 2020 May;17(5):533-535. doi: 10.1038/s41423-020-0402-2. Epub 2020 Mar 19.
7
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病（COVID-19）疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
8
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis.巨噬细胞活化综合征：导致脓毒症早期死亡的独特实体。
Front Immunol. 2019 Jan 31;10:55. doi: 10.3389/fimmu.2019.00055. eCollection 2019.
Zotero 插件